OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer
oncodaily - OPTIMA is one of the most important de-escalation studies presented at the 2026 ASCO Annual Meeting, because it addresses a daily clinical dilemma in early breast cancer: which patients truly […]
AI Summary: The OPTIMA trial demonstrated that using the Prosigna genomic test to select low‑risk ER+/HER2− early breast cancer patients allows omission of adjuvant chemotherapy without compromising disease control. The de‑escalation approach reduced exposure to chemo toxicity and supports molecular risk stratification to spare large numbers of patients unnecessary treatment — elegant, evidence‑based thrift.
DESTINY-Lung03: T-DXd Confirms Activity in HER2-Overexpressing NSCLC, but Triplet Therapy Falls Short
oncodaily - DESTINY-Lung03 Part 1 provides an important signal for the treatment of HER2-overexpressing non-small cell lung cancer (NSCLC). The study confirms that trastuzumab deruxtecan (T-DXd) monotherapy has clinically meaningful activity in […]
AI Summary: DESTINY‑Lung03 data confirmed trastuzumab deruxtecan has tangible activity in HER2‑overexpressing non‑small‑cell lung cancer, producing notable responses. Attempts to escalate to triplet regimens failed to add benefit, prompting a reality check on combination complexity and the need for sharper biomarkers rather than more drugs.
Listen to the Latest ‘KFF Health News Minute’
kffhealthnews - The "KFF Health News Minute" brings original health care and health policy reporting from our newsroom to the airwaves each week.
AI Summary: A phase 2 study investigated FGFR inhibition with rogaratinib in succinate dehydrogenase–deficient gastrointestinal stromal tumors. Results reported tumor control in this rare molecular subset, offering a targeted therapeutic approach where options are sparse and validating FGFR as a biologic vulnerability in SDH‑deficient GIST.
MajesTEC-9 Results at ASCO 2026: Teclistamab Monotherapy Demonstrates Superiority Over PVd/Kd in Earlier-Line RRMM
oncodaily - At ASCO 2026, results from MajesTEC-9 (NCT05572515), the first phase 3 study of teclistamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM) after 1-3 prior lines of therapy, […]
AI Summary: Teclistamab monotherapy demonstrated superior progression-free survival and response rates versus pomalidomide‑based (PVd) and carfilzomib‑based (Kd) regimens in earlier-line relapsed/refractory multiple myeloma, showing durable remissions at 18 months. The data suggest a shift toward bispecific antibody therapy earlier in the treatment sequence for many patients.
FDA Approves Decnupaz (pivekimab sunirine-pvzy), the First ADC for Adults With BPDCN
oncodaily - On May 27, 2026, the U.S. FDA granted approval to pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for the treatment of adults with blastic plasmacytoid […]
AI Summary: The FDA approved pivekimab sunirine (Decnupaz/pvzy), the first antibody‑drug conjugate for blastic plasmacytoid dendritic cell neoplasm (BPDCN), marking a regulatory win for an ultra‑rare blood cancer. The decision underscores ADCs’ growing role in niche hematologic malignancies and anchors AbbVie’s expanding ADC strategy.